Physician profile
Michael D Bain
NPI 1528551488
$2,532.16
in general payments reported to CMS, 2019-2025
24 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $555 · 2021: $334 · 2022: $190 · 2023: $179 · 2024: $136 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $490.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $497.58 | 2019-2025 | Ubrelvy, Qulipta |
| Regeneron Healthcare Solutions, INC. | $465.95 | 2019-2021 | |
| Pfizer INC. | $420.77 | 2019-2024 | |
| Allergan, INC. | $217.07 | 2019-2021 | |
| Grifols USA, LLC | $124.99 | 2020 | |
| Novo Nordisk INC | $123.94 | 2020-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $119.62 | 2019 | |
| Glaxosmithkline, LLC. | $115.10 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $93.56 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $48.92 | 2022 | |
| Merck Sharp & Dohme LLC | $45.29 | 2019-2021 | |
| Exact Sciences Corporation | $41.02 | 2023 | Cologuard Collection Kit |
| Qiagen, LLC | $39.50 | 2021-2022 | |
| Genzyme Corporation | $20.71 | 2020 | |
| Seqirus USA INC | $20.48 | 2024 | Flucelvax, Fluad |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $19.75 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.21 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.97 | 2025 | Caplyta |
| Corium, LLC | $15.82 | 2023 | Azstarys |
| Viiv Healthcare Company | $15.38 | 2024 | Apretude |
| Otsuka America Pharmaceutical, INC. | $14.88 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $13.33 | 2020 | |
| Philips North America LLC | $13.30 | 2019 | |
| Amarin Pharma, INC. | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.